secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0000950170-25-034574
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology Q4 net loss $29.2M; cash $131.3M; evorpacept data positive; workforce cut
--------------------------------------------------------------------------------

- GAAP net loss Q4 2024: ($29.2M) or ($0.55)/share, improved from ($45.5M) or ($0.93)/share in Q4 2023.
- Cash & equivalents $131.3M as of Dec 31, 2024; expects cash runway into Q4 2026 after ~30% workforce reduction.
- ASPEN-06 Phase 2: evorpacept combo cORR 48.9% vs 24.5% control in HER2+ gastric cancer; median DOR 15.7 vs 9.1 months.
- Leadership changes: appointed CBO, CMO, CFO; founder Jaume Pons steps down as President, becomes Senior Scientific Advisor.
- Upcoming catalysts: ASPEN-03/04 HNSCC topline data Q2 2025; regulatory guidance on gastric cancer path Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000095017025034574/0000950170-25-034574-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000095017025034574/alxo-20250306.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-034574

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer